markets.businessinsider.com
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option if confirmed in phase 3 trials.
Adults with moderate-to-severe UC or Crohn’s disease, clinicians treating IBD, researchers in IBD drug development, and patients interested in emerging biologic therapies.
What To Know
New detailed phase 2b results for duvakitug (a monoclonal antibody targeting TL1A) were presented at ECCO 2025 from the RELIEVE UCCD study, including efficacy and safety data in both ulcerative colitis and Crohn’s disease cohorts.
Reported endpoints include clinical remission, endoscopic response and remission, and histological-endoscopic mucosal improvement at week 14 across two dose levels, with higher response at the 900 mg dose. The company says findings will support a planned phase 3 program beginning in H2 2025.
The press release is from Sanofi and Teva and summarizes trial outcomes and safety observations; it notes duvakitug is investigational and not yet evaluated by regulators. It does not provide full study data or independent peer review; detailed methods and full datasets were not included in this release.
If you want the original source, read the ECCO presentation abstracts or the full RELIEVE UCCD study report when available for complete efficacy, safety, and subgroup details.
This is a company press release summarizing phase 2b results presented at a conference. Results are preliminary; duvakitug remains investigational and not approved by regulators. Look for peer-reviewed publications or full conference abstracts for detailed methods, endpoints, and safety data before drawing conclusions.
